Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBT (2023 - 2025)

Historic EBT for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to $304000.0.

  • Immunocore Holdings' EBT fell 9501.07% to $304000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year increase of 4767.75%. This contributed to the annual value of -$52.9 million for FY2024, which is 1306.13% up from last year.
  • Per Immunocore Holdings' latest filing, its EBT stood at $304000.0 for Q3 2025, which was down 9501.07% from -$9.7 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year EBT high stood at $6.1 million for Q3 2024, and its period low was -$52.9 million during Q4 2021.
  • In the last 5 years, Immunocore Holdings' EBT had a median value of -$17.1 million in 2022 and averaged -$18.0 million.
  • In the last 5 years, Immunocore Holdings' EBT soared by 73351.57% in 2024 and then tumbled by 9501.07% in 2025.
  • Over the past 5 years, Immunocore Holdings' EBT (Quarter) stood at -$52.9 million in 2021, then soared by 67.05% to -$17.4 million in 2022, then crashed by 47.17% to -$25.6 million in 2023, then rose by 3.2% to -$24.8 million in 2024, then skyrocketed by 101.22% to $304000.0 in 2025.
  • Its EBT stands at $304000.0 for Q3 2025, versus -$9.7 million for Q2 2025 and $6.1 million for Q1 2025.